Speaking to ecancer from the Academy for Cancer Education (ACE) 3rd Asia Pacific Prostate Cancer Conference (APPCC) in Shanghai, Prof Li Ping Xie from the Zhejiang University School of Medicine, Hangzhou, China, interviews Prof Paul de Souza from the University of Western Sydney, Sydney, Australia.
Prof de Souza outlines how he thinks treatment choice will change over the next five years. With the expected increase in treatment choice, deciding which treatment to give each patient will be a challenge.
He also comments on how the sequence of combination therapy should be addressed, e.g. with personalised medicine and biomarker studies.
He then comments on the future role of chemotherapy in mCRPC, noting that it will have a place. Prof de Souza moves on to outline his preferred treatment choices for unfit and/or elderly patients.
This video is sponsored by an educational grant from Janssen Asia Pacific, pharmaceutical companies of Johnson & Johnson